Swie Swat Oei
Erasmus University Rotterdam
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Swie Swat Oei.
International Journal of Radiation Oncology Biology Physics | 2002
Suresh Senan; Sjaak Burgers; M.J. Samson; Rob J. van Klaveren; Swie Swat Oei; John R. van Sörnsen de Koste; P. Voet; Frank J. Lagerwaard; Jan Maarten van Haarst; Joachim Aerts; Jan P. van Meerbeeck
PURPOSE To establish the recurrence patterns when elective mediastinal irradiation was omitted, patients with Stage III non-small-cell lung cancer were treated with sequential chemotherapy (CHT) and involved-field radiotherapy (RT). METHODS AND MATERIALS Fifty patients were treated with either two or four cycles of induction CHT, followed by once-daily involved-field RT to 70 Gy, delivered using three-dimensional treatment planning. The contoured gross tumor volume consisted of the pre-CHT tumor volume and nodes with a short-axis diameter of > or = 1 cm. Patients were reevaluated at 3 and 6 months after RT using bronchoscopy and chest CT. Elective nodal failure was defined as recurrence in the regional nodes outside the clinical target volume, in the absence of in-field failure. RESULTS Of 43 patients who received doses > or = 50 Gy, 35% were disease free at last follow-up; in-field recurrences developed in 27% (of whom 16% had exclusively in-field recurrences); 18% had distant metastases exclusively. No elective nodal failure was observed. The median actuarial overall survival was 18 months (95% confidence interval 14-22) and the median progression-free survival was 12 months (95% confidence interval 6-18). CONCLUSION Omitting elective mediastinal irradiation did not result in isolated nodal failure. Future studies of concurrent CHT and RT for Stage III non-small-cell lung cancer should use involved-field RT to limit toxicity.
Radiotherapy and Oncology | 2017
A. Bruynzeel; Frank J. Lagerwaard; O. Bohoudi; S. Tetar; N. Haasbeek; Swie Swat Oei; B.J. Slotman; M. Meijerink; S. Senan; M. Palacios
Purpose or Objective The duodenum is the primary dose-limiting organ when performing SBRT for locally advanced pancreatic cancer (LAPC). With technical and imaging advancements, the incidence of grade ≥3 small bowel toxicity (bleeding, perforation, strictures) has decreased to
Cureus | 2018
Shyama Tetar; A. Bruynzeel; Roosje Bakker; Marloes Jeulink; Ben J. Slotman; Swie Swat Oei; Cornelis J.A. Haasbeek; Karel De Jong; Suresh Senan; Frank J. Lagerwaard
Purpose Magnetic resonance imaging-guided radiation therapy (MRgRT) requires patient positioning within the MR bore and prolonged MR imaging during delivery, both of which are new in radiation oncology. Patient tolerance of MRgRT was prospectively evaluated using patient-reported outcome questionnaires (PRO-Q). Methods Our MRgRT procedure involves daily high-resolution MR scanning, limited re-contouring, daily plan re-optimization, quality assurance (QA), and gated delivery. Patients with claustrophobia are excluded. Mean fraction duration was 45 and 60 minutes for stereotactic treatments during free-breathing and breath-hold, respectively. Patient-controlled video-feedback was used for breath-hold delivery. PRO-Qs collected in the first 150 patients treated included questions on MR-related complaints and also evaluated aspects of active participation. Results Almost one-third of patients (29%) scored at least one PRO-Q item on MR-related complaints as ‘moderate’ or ‘very much’, with noise, feeling cold, and paresthesia being the most frequently scored in this way. Considerable anxiety was reported by 5%, but no medication was required for this in any patient. Patient participation in video feedback for breath-hold delivery was appreciated by the majority of patients, all of whom completed the procedure. Only 5% of patients considered treatment duration to be unacceptably long. Conclusion Despite the lengthy MRgRT procedure, outcomes of PRO-Q indicate that it was well-tolerated by patients.
International Journal of Radiation Oncology Biology Physics | 2001
Frank J. Lagerwaard; John R. van Sörnsen de Koste; Margriet R.J Nijssen-Visser; Regine H. Schuchhard-Schipper; Swie Swat Oei; Aristoteles Munne; Suresh Senan
Radiotherapy and Oncology | 2001
John R. van Sörnsen de Koste; Frank J. Lagerwaard; Regine H. Schuchhard-Schipper; Margriet R.J Nijssen-Visser; P. Voet; Swie Swat Oei; Suresh Senan
Lung Cancer | 2002
F.J. Lagerwaard; Paul J.M van de Vaart; P. Voet; Margriet R.J Nijssen-Visser; Regine H. Schuchhard-Schipper; Hans Joosten; Swie Swat Oei; Suresh Senan
International Journal of Radiation Oncology Biology Physics | 2001
S. Senan; Jacobus A. Burgers; M.J. Samson; R.J. van Klaveren; Swie Swat Oei; J.R. van Sornsen de Koste; P. Voet; J.M. van Haarst; F.J. Lagerwaard; J. Van Meerbeeck
International Journal of Radiation Oncology Biology Physics | 2017
F.J. Lagerwaard; A. Bruynzeel; S. Tetar; Swie Swat Oei; Cornelis J.A. Haasbeek; B.J. Slotman; S. Senan; O. Bohoudi; M. Palacios
International Journal of Radiation Oncology Biology Physics | 2017
A. Bruynzeel; Frank J. Lagerwaard; S. Tetar; Swie Swat Oei; Cornelis J.A. Haasbeek; O. Bohoudi; B.J. Slotman; M. Meijerink; S. Senan; M. Palacios
European Journal of Cancer | 2001
P.J.M. van de Vaart; S. Senan; P. Voet; Regine H. Schuchhard-Schipper; Margriet R.J Nijssen-Visser; J. van Sornsen de Koste; Swie Swat Oei; P. Joosten; F.J. Lagerwaard